ClinicalTrials.gg
Not yet recruitingNCT06487000Updated Aug 28, 2026

Determine the Dose-dependent Efficacy and Safety of EC-18 in Patients With Moderate to Severe Atopic Dermatitis

A Phase 2 interventional study of EC-18 and Placebo EC-18 in Atopic Dermatitis, sponsored by Enzychem Lifesciences Corporation. Not yet recruiting. Open to participants aged 19 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-08-28.

Sponsored by Enzychem Lifesciences Corporation · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
19 Years to 79 Years
Sex
All
01

Study summary

To evaluate the efficacy and safety of oral administration of dose-dependent EC-18 for 16 weeks in patients with moderate to severe atopic dermatitis

Read the detailed description

This study will utilize a randomized, double blind, placebo-controlled, parallel-group, multi-Center design. The Experimental group 1 will receive 1000mg of EC-18[2 capsules of EC-18 500mg, 2 capsules of placebo]. The experimental group 2 will receive 2000mg of EC-18 [4 capsules of EC-18]. The placebo group will receive 4 capsules of placebo. The time frame of this clinical trial will consist 16 weeks.

02

Conditions studied

  • Atopic Dermatitis

Browse trials for

03

In context

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

This study's planned enrollment of 150 is above the median of 82 across 1,249 interventional studies indexed under Dermatitis, Atopic.

Browse Dermatitis, Atopic studies →

Lead sponsor

Enzychem Lifesciences Corporation is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

At the time of screening:

  • aged 19 to under 80 at the time of written consent.
  • Patients diagnosed with atopic dermatitis according to the Hanifin and Rajka criteria (≥3 major symptoms out of 4 and ≥3 minor symptoms out of 23) for at least 12 months prior to screening
  • Patients requiring systemic therapy for disease control due to either a documented inadequate response to topical drug treatment for at least 4 weeks (within 6 months prior to screening visit), or where topical therapy is medically not recommended (due to significant side effects or safety concerns)
  • Patients with Moderate to Severe Atopic dermatitis

    • BSA ≥ 10%
    • EASI score ≥16
    • IGA score ≥3
    • Pruritus NRS score ≥3
  • Patients who have been fully informed about this clinical trial, have voluntarily decided to participate, and have provided written consent to faithfully comply with the trial requirements.

At the time of baseline visit

  • Signed
  • Patients who have used emollients continuously for the 7 days prior to baseline visit

Exclusion criteria

Exclusion Criteria:

  • Patients with serious skin conditions other than atopic dermatitis (e.g. psoriasis, discoid lupus erythematosus, or erythema multiforme that, as judged by the investigator, would adversely affect the evaluation of atopic dermatitis)
  • Patients with a history of chronic
  • Patients with ongoing malignant tumors at screening or diagnosed within the last 5 years
  • Patients who have undergone bone marrow or organ transplantation
  • Patients with hypertension (e.g. systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg)
  • Patients with ulcerative or erosive lesions
  • Patients with Netherton's Syndrome
  • Patients with severe infections (e.g. infections requiring prolonged antibiotic or immunotherapy treatment) or severe trauma as judged by the investigator
  • Patients with positive serum test results at screening (HBs Ag, Ab, Ab). However, patients with a positive HCV Ab result may be eligible if they have achieved HCV RNA negativity after treatment
  • Patients at screening (Visit 1) with laboratory test results falling under the following criteria:

    • ≥ 7%(Despite medication treatment)
    • and AST ≥ 5 times the (ULN)
    • (CKD-EPI_ \< 30 ml/ min/1.73m²
    • Serum potassium > 5.5 mEq/L
    • LDL-C >190mg/dL or TC > 500mg/dl (Despite medication treatment)
  • Patients with reactions to the components of the durg or its formulations
  • Treatment with topical , local calcineurin inhibitors, topical Janus kinase inhibitors, Tars, antibiotic cream, topical or oral antihistamines within the past 7 days prior to baseline
  • Patients who have undergone sunbathing, tanning bed use, ultraviolet B (UVB) therapy, or PUVA (psoralen + ultraviolet A (UVA)) therapy for relief of atopic dermatitis symptoms within the 14 days prior to baseline
  • Treatment with systemic immunosuppressants/immunomodulators and/or systemic corticosteroids within the 28 days prior to baseline (patients who have used stable doses of inhaled corticosteroids or nasal sprays for more than 3 months are eligible to participate)
  • Patients who have received treatment with biologics other than dupilumab within 3 months prior to baseline.
  • Patients who have received treatment with dupilumab within 3 months prior to baseline
  • Patients with a history of drug or alcohol abuse within 1 year prior to screening
  • Pregnant or breastfeeding women.
  • Women who test positive for pregnancy at screening or who plan to become pregnant during the clinical trial period and up to one month after the end of the investigational drug administration, or who do not agree to use appropriate *, and men.

    • Appropriate contraception: complete abstinence, hormonal contraceptives without known drug interactions [levonorgestrel intrauterine system (IUS) (Mirena), medroxyprogesterone], surgical sterilization (vasectomy, bilateral tubal ligation, etc.). Note that periodic abstinence (e.g., ovulation timing, symptothermal method, or post- ovulation) or withdrawal is not considered appropriate contraception.
  • Patients who have received any investigational drug within 6 months prior to screening (those who have not received an investigational drug or who have participated in non-interventional observational studies are eligible)
  • Other patients deemed unsuitable for participation in this clinical trial by the investigator.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    EC-18 1000mg

    \[EC-18 2 capsules / Placebo 2 capsules\]

    Drug: EC-18 · Drug: Placebo EC-18

  • Experimental
    EC-18 2000mg

    \[EC-18 4 capsules\]

    Drug: EC-18

  • Placebo comparator
    Placebo

    \[Placebo 4 capsules\]

    Drug: Placebo EC-18

Interventions

06

What researchers measure

Primary outcomes

  1. Change in EASI score at 16 weeks compared to baseline

    Eczema Area Severity Index (EASI) score: Sum of the 4 region scores (Head/neck, Trunk , Upper extremities, Lower extremities) Score range: \[0=none \~ 72=very severe\]

    Time frame: Baseline, week 16

Secondary outcomes

  1. Change in EASI score at 4, 8, and 12 weeks compared to baseline.

    Eczema Area Severity Index (EASI) score: Sum of the 4 region scores (Head/neck, Trunk , Upper extremities, Lower extremities) Score range: \[0=none \~ 72=very severe\]

    Time frame: Baseline, week 4, 8, 12

  2. Percentage change in EASI score at 4, 8, 12, and 16 weeks compared to baseline

    Eczema Area Severity Index (EASI) score: Sum of the 4 region scores (Head/neck, Trunk , Upper extremities, Lower extremities) Score range: \[0=none \~ 72=very severe\]

    Time frame: Baseline, week 4, 8, 12, 16

  3. Proportion of subjects achieving EASI-50, EASI-75, and EASI-90 at 4, 8, 12, and 16 weeks compared to baseline.

    Eczema Area Severity Index (EASI) score: Sum of the 4 region scores (Head/neck, Trunk , Upper extremities, Lower extremities) Score range: \[0=none \~ 72=very severe\]

    Time frame: Baseline, week 4, 8, 12, 16

  4. Change in IGA score at 4, 8, 12, and 16 weeks compared to baseline.

    Investigator's Global Assessment(IGA) score: \[0 = Clear, 1 = Almost clear, 2 = Mild, 3 = Moderate, 4 = Severe\]

    Time frame: Baseline, week 4, 8, 12, 16

  5. Proportion of subjects with an IGA score of 0 or 1 and at least a 2-point reduction in IGA score at 4, 8, 12, and 16 weeks compared to baseline.

    Investigator's Global Assessment(IGA) score: \[0 = Clear, 1 = Almost clear, 2 = Mild, 3 = Moderate, 4 = Severe\]

    Time frame: Baseline, week 4, 8, 12, 16

  6. Change in pruritus NRS score at 4, 8, 12, and 16 weeks compared to baseline. Change in pruritus NRS score at 4, 8, 12, and 16 weeks compared to baseline. Change in pruritus NRS score at 4, 8, 12, and 16 weeks compared to baseline.

    Pruritus Numerical Rating Scale(NRS): The scale of perceived itchiness from \[0=none to 10=very severe\]

    Time frame: Baseline, week 4, 8, 12, 16

  7. Percentage change in pruritus NRS score at 4, 8, 12, and 16 weeks compared to baseline.

    Pruritus Numerical Rating Scale(NRS): The scale of perceived itchiness from \[0=none to 10=very severe\]

    Time frame: Baseline, week 4, 8, 12, 16

  8. Proportion of subjects with a pruritus NRS score reduction of 4 points or more at 4, 8, 12, and 16 weeks compared to baseline.

    Pruritus Numerical Rating Scale(NRS): The scale of perceived itchiness from \[0=none to 10=very severe\]

    Time frame: Baseline, week 4, 8, 12, 16

  9. Change in sleep disturbance NRS score at 4, 8, 12, and 16 weeks compared to baseline.

    Sleep Disturbance Numerical Rating Scale(NRS): The scale of perceived sleep disturbance from \[0=none to 10=very severe\]

    Time frame: Baseline, week 4, 8, 12, 16

  10. Frequency and duration of application of the rescue medication (tacrolimus ointment).

    Time frame: week 4 ~ week 16

Other outcomes

  1. (Exploratory) Change in DLQI score at 4, 8, 12, and 16 weeks compared to baseline.

    Dermatology Life Quality Index (DLQI) score \[0-1\] = No effect on patient's life \[2-5\] = Minimal effect on patient's life \[6-10\] = Moderate effect on patient's life \[11-20\] = Very large effect \[21 - 30\] = Extremely large effect

    Time frame: Baseline, week 4, 8, 12, 16

  2. (Exploratory) Changes in inflammatory biomarker (cytokine) levels at 4, 8, 12, and 16 weeks compared to baseline.

    \[IL-4, IL-13, IL-6, IFN- γ, IL-17A, IgE\]

    Time frame: Baseline, weeks 4, 8, 12, 16

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2027; primary completion for Oct 2027, 5 months later.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's planned 5 months is below that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2024
First posted
Jul 5, 2024
StartEst.
May 2027
Primary completionEst.
Oct 2027
CompletionEst.
Dec 2027
Last update
Aug 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06487000
Lead sponsor
Enzychem Lifesciences Corporation
Responsible party
Sponsor
First posted
Jul 5, 2024
Start date
May 2027 (estimated)
Primary completion
Oct 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Aug 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mosedipimod

Start the discussion